Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Brii Biosciences Limited ( (HK:2137) ) has issued an update.
Brii Biosciences Limited has scheduled a board meeting for March 19, 2026 to review and approve its audited annual results for the year ended December 31, 2025. The board will also consider publication of these results and address other corporate matters, signaling the upcoming disclosure of the company’s financial and operational performance to shareholders and the market.
The announcement confirms the current composition of Brii Biosciences’ board, including its chairman and both executive and independent non-executive directors. This underlines the company’s established governance framework as it prepares for a key financial reporting milestone that may influence investor assessment and market perception of its progress.
The most recent analyst rating on (HK:2137) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Brii Biosciences Limited stock, see the HK:2137 Stock Forecast page.
More about Brii Biosciences Limited
Brii Biosciences Limited is a biotechnology company incorporated in the Cayman Islands and listed in Hong Kong, focusing on the development of innovative biopharmaceuticals. The company operates through a board comprising executive and independent non-executive directors, reflecting a governance structure aligned with international capital market standards.
YTD Price Performance: -2.13%
Average Trading Volume: 1,302,127
Technical Sentiment Signal: Sell
Current Market Cap: HK$995.7M
For an in-depth examination of 2137 stock, go to TipRanks’ Overview page.